HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Adenocarcinoma
/ epidemiology
Adult
Aged
Biomarkers, Tumor
/ genetics
Cell Proliferation
/ genetics
Esophageal Neoplasms
/ epidemiology
Esophagectomy
Esophagogastric Junction
/ pathology
Female
Gene Amplification
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Humans
In Situ Hybridization, Fluorescence
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Staging
Prognosis
Receptor, ErbB-2
/ genetics
Tissue Array Analysis
Esophageal adenocarcinoma (EAC)
Fluorescence-in-situ-hybridization (FISH)
HER2/neu (ERBB2)
Immunohistochemistry
Prognosis
Tissue microarray (TMA)
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Jan 2019
08 Jan 2019
Historique:
received:
28
06
2018
accepted:
21
12
2018
entrez:
10
1
2019
pubmed:
10
1
2019
medline:
16
4
2019
Statut:
epublish
Résumé
HER2 (ERBB2 or HER2/neu) is a tyrosine-kinase increasing cell proliferation. Overexpression/amplification of HER2 is correlated with worse prognosis in solid malignancies. Consequently, HER2 targeting is established in breast and upper gastrointestinal tract cancer. There are conflicting data concerning the impact of HER2 overexpression on esophageal adenocarcinoma (EAC), as most studies do not differ between cancers of the esophagus/gastroesophageal junction and the stomach. The aim of this study was to analyze the expression/amplification of HER2 in EAC in correlation to clinicopathological data to verify its prognostic impact. We analyzed 428 EAC patients that underwent transthoracic thoraco-abdominal esophagectomy between 1997 and 2014. We performed HER2 immunohistochemistry (IHC) according to the guidelines and fluorescence-in-situ-hybridization (FISH) for IHC score2+, using tissue micro arrays (TMA) with up to eight biopsies from the surface and infiltration area of a single tumor for evaluating HER2-heterogeneity and single-spot TMA. The HER2-status was correlated with clinicopathological data. HER2-positivity was found in up to 14.9% in our cohort (IHC score 3+ or IHC score 2+ with gene amplification) and demonstrated a significantly better overall survival (OS) in correlation to HER2-negative tumors (median OS 70.1 vs. 24.6 months, p = 0.006). HER2-overexpression was more frequently seen in lower tumor stages (pT1/pT2, p = 0.038), in the absence of lymphatic metastases (pN0/pN+, p = 0.020), and was significantly associated with better histological grading (G1/G2) (p = 0.041). We demonstrated a positive prognostic impact of HER2 overexpression in a large cohort of EAC, contrary to other solid malignancies including gastric cancer and breast cancer, but consistent to the results of a large study on EAC from 2012.
Sections du résumé
BACKGROUND
BACKGROUND
HER2 (ERBB2 or HER2/neu) is a tyrosine-kinase increasing cell proliferation. Overexpression/amplification of HER2 is correlated with worse prognosis in solid malignancies. Consequently, HER2 targeting is established in breast and upper gastrointestinal tract cancer. There are conflicting data concerning the impact of HER2 overexpression on esophageal adenocarcinoma (EAC), as most studies do not differ between cancers of the esophagus/gastroesophageal junction and the stomach. The aim of this study was to analyze the expression/amplification of HER2 in EAC in correlation to clinicopathological data to verify its prognostic impact.
METHODS
METHODS
We analyzed 428 EAC patients that underwent transthoracic thoraco-abdominal esophagectomy between 1997 and 2014. We performed HER2 immunohistochemistry (IHC) according to the guidelines and fluorescence-in-situ-hybridization (FISH) for IHC score2+, using tissue micro arrays (TMA) with up to eight biopsies from the surface and infiltration area of a single tumor for evaluating HER2-heterogeneity and single-spot TMA. The HER2-status was correlated with clinicopathological data.
RESULTS
RESULTS
HER2-positivity was found in up to 14.9% in our cohort (IHC score 3+ or IHC score 2+ with gene amplification) and demonstrated a significantly better overall survival (OS) in correlation to HER2-negative tumors (median OS 70.1 vs. 24.6 months, p = 0.006). HER2-overexpression was more frequently seen in lower tumor stages (pT1/pT2, p = 0.038), in the absence of lymphatic metastases (pN0/pN+, p = 0.020), and was significantly associated with better histological grading (G1/G2) (p = 0.041).
CONCLUSION
CONCLUSIONS
We demonstrated a positive prognostic impact of HER2 overexpression in a large cohort of EAC, contrary to other solid malignancies including gastric cancer and breast cancer, but consistent to the results of a large study on EAC from 2012.
Identifiants
pubmed: 30621632
doi: 10.1186/s12885-018-5242-4
pii: 10.1186/s12885-018-5242-4
pmc: PMC6325716
doi:
Substances chimiques
Biomarkers, Tumor
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Références
Ann Oncol. 2001;12 Suppl 1:S3-8
pubmed: 11521719
Oncology. 2001;61 Suppl 2:67-72
pubmed: 11694790
Oncogene. 2003 Sep 29;22(42):6570-8
pubmed: 14528282
N Engl J Med. 2003 Dec 4;349(23):2241-52
pubmed: 14657432
J Cell Physiol. 2004 Sep;200(3):343-50
pubmed: 15254961
Mod Pathol. 2007 Jan;20(1):120-9
pubmed: 17143264
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Histopathology. 2008 Jun;52(7):797-805
pubmed: 18422971
J Cell Mol Med. 2009 Sep;13(9B):3826-33
pubmed: 19292734
Pathologe. 2010 May;31(3):208-17
pubmed: 20443098
Methods Mol Biol. 2010;664:1-16
pubmed: 20690047
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Mod Pathol. 2011 Jul;24(7):908-16
pubmed: 21516080
Gastric Cancer. 2012 Apr;15(2):137-43
pubmed: 21842172
Histopathology. 2011 Nov;59(5):832-40
pubmed: 22092394
Clin Cancer Res. 2012 Jan 15;18(2):546-54
pubmed: 22252257
Arch Pathol Lab Med. 2012 Jun;136(6):691-7
pubmed: 22646280
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Ann Oncol. 2012 Oct;23(10):2656-62
pubmed: 22689179
J Gastrointest Surg. 2012 Oct;16(10):1821-9
pubmed: 22843084
J Clin Oncol. 2012 Nov 10;30(32):3932-8
pubmed: 22987085
Ann Oncol. 2013 May;24(5):1253-61
pubmed: 23233651
Nat Genet. 2013 May;45(5):478-86
pubmed: 23525077
Arch Pathol Lab Med. 2014 Feb;138(2):241-56
pubmed: 24099077
Ann Oncol. 2013 Dec;24(12):3035-9
pubmed: 24114855
Pharmacol Res. 2014 Jan;79:34-74
pubmed: 24269963
J Cancer Res Clin Oncol. 2015 Aug;141(8):1343-51
pubmed: 25544671
Best Pract Res Clin Gastroenterol. 2015 Feb;29(1):193-209
pubmed: 25743466
J Clin Diagn Res. 2015 Mar;9(3):EC06-10
pubmed: 25954623
Endosc Int Open. 2015 Apr;3(2):E165-70
pubmed: 26135662
BMC Cancer. 2016 Jul 07;16:406
pubmed: 27387915
Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363
pubmed: 27841667
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
World J Surg Oncol. 2017 Mar 21;15(1):68
pubmed: 28327158
Mol Clin Oncol. 2017 May;6(5):639-642
pubmed: 28529740
Am J Gastroenterol. 2017 Aug;112(8):1247-1255
pubmed: 28585555
Ann Surg. 2018 Aug;268(2):289-295
pubmed: 28628563
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Arch Pathol Lab Med. 2018 Apr;142(4):516-522
pubmed: 28782986
J Clin Pathol. 2018 May;71(5):451-462
pubmed: 29138285
Oncotarget. 2017 Nov 25;8(65):109457-109467
pubmed: 29312620
Science. 1986 Jun 27;232(4758):1644-6
pubmed: 3012781
Clin Cancer Res. 2018 Dec 15;24(24):6248-6256
pubmed: 30348637
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106